← Eichor
Study identifier: NCT04304625 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA

Condition: Postpartum Hemorrhage  ·  Sponsor: University Hospital, Bordeaux

PhasePhase 3
Planned participants1380
Who can joinFemale, 18 Years to 65 Years
Healthy volunteersNo

About this study

Several randomized, controlled trials, mostly involving women undergoing cesarean delivery, have shown that the prophylactic intravenous administration of 1 g of tranexamic acid after childbirth reduced blood loss. Most were small, single-centre trials with considerable methodologic limitations. It is important to emphasize that none of these RCTs has included women at increased risk of PPH such as placenta previa, a context in which the prevalence of moderate and severe blood loss is significantly higher and where the magnitude of the effect of TXA may highly differ compared to low risk women

This description comes directly from the study's public registry record.

Talk to the study team

Loic Sentilhes, MD, PhD  ·  +335 56 79 55 79  ·  loic.sentilhes@chu-bordeaux.fr

Aurélie Darmaillacq  ·  aurelie.darmaillacq@chu-bordeaux.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU BordeauxBordeaux, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04304625